BN Business News
Adicionar empresa →
Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.

Negócios · 01/08/20112 min de leitura

Prescription Drug User Fee Rates for Fiscal Year 2012

Tradução automática local · Idioma original da fonte

Resumo

The Food and Drug Administration (FDA) is announcing the rates for prescription drug user fees for fiscal year (FY) 2012. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2007 (Title 1 of the Food and Drug Administration Amendments Act of 2007 (FDAAA)) (PDUFA IV), authorizes FDA to collect user fees for certain applications for approval of drug and biological products, on establishments where the products are made, and on such products. Base revenue amounts to be generated from PDUFA fees were established by PDUFA IV, with provisions for certain adjustments. Fee revenue amounts for applications, establishments, and products are to be established each year by FDA so that one-third of the PDUFA fee revenues FDA collects each year will be generated from each of these categories. This document establishes fee rates for FY 2012 for application fees for an application requiring clinical data ($1,841,500), for an application not requiring clinical data or a supplement requiring clinical data ($920,750), for establishment fees ($520,100), and for product fees ($98,970). These fees are effective on October 1, 2011, and will

Idioma original da fonte: Federal Register — Health and Human ServicesAbrir o comunicado original →

Explorar análises

Análises empresariais →